Drugs / ATL1102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05938023 | May 2023 → Nov 2024 | Duchenne muscular dystrophy | Percheron Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2009-04-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva to Present New Data on its Innovative Therapies for Multiple Sclerosis and Parkinson's Disease at the Upcoming 2009 American Academy of Neurology Annual Meeting tevapharm.com ↗
VLA-4 Antisense An Oligonucleotide Targeting VLA-4 mRNA (ATL1102) Significantly Reduces New Active Lesions in Patients with RR-MS |
| 2008-09-22 | Ionis Pharmaceuticals | Results ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis ionis.com ↗
The study met its primary endpoint showing a significant reduction by 54.4% (p=0.01) in cumulative number of new active lesions in the ATL/TV1102 treated patients compared to placebo. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2009-04-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva to Present New Data on its Innovative Therapies for Multiple Sclerosis and Parkinson's Disease at the Upcoming 2009 American Academy of Neurology Annual Meeting tevapharm.com ↗ |
| 2008-09-22 | Ionis Pharmaceuticals | ATL/TV1102 Trial Results Presented at World Congress on Treatment and Research in Multiple Sclerosis ionis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATL1102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05938023 ↗ |
| Route | Subcutaneous | “ATL1102 25mg administered subcutaneously once weekly” NCT05938023 ↗ |